916211-79-5

Basic information

• Product Name: 3-Chloro-1H-pyrazol-5-aMine
• Synonyms: 3-Chloro-1H-pyrazol-5-aMine;5-chloro-1H-pyrazol-3-aMine;EOS-61385
• CAS NO: 916211-79-5
• Molecular Formula: C₃H₄ClN₃
• Molecular Weight: 117.53696
• Mol File: 916211-79-5.mol

Chemical Properties

• Boiling Point: 394.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.562±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.32±0.10(Predicted)
• CAS DataBase Reference: 3-Chloro-1H-pyrazol-5-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-1H-pyrazol-5-aMine(916211-79-5)
• EPA Substance Registry System: 3-Chloro-1H-pyrazol-5-aMine(916211-79-5)

Safety Data

• Hazardous Substances Data: 916211-79-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-chloro-1H-pyrazol-5-amine is used as a chemical intermediate for the synthesis of a wide range of pharmaceuticals and agrochemicals. Its versatility allows for the creation of various drug molecules, contributing to the development of new treatments and therapies.
Used in Drug Development:
3-chloro-1H-pyrazol-5-amine is used as a starting material in the development of new drugs due to its potential biological activities. Its unique structure and properties make it a valuable component in the design and synthesis of innovative pharmaceutical compounds.
Used in Agrochemical Production:
In addition to its applications in the pharmaceutical industry, 3-chloro-1H-pyrazol-5-amine is also used as a building block in the production of agrochemicals. Its role in creating effective and targeted agrochemicals contributes to advancements in agriculture and crop protection.

Upstream product

• 1369959-12-5 3-chloro-5-nitro-1H-pyrazole 
• 28491-52-3 5-amino-1,2-dihydropyrazol-3-one 

Downstream Products

• 1369958-92-8 C₂₄H₂₁Cl₃FN₅O 

Relevant articles and documents

COMPOUNDS FOR MALT1 DEGRADATION

Provided herein are bifunctional compounds that inhibit MALTl and/or promote targeted ubiquitination for the degradation of MALTl. In particular, provided are compounds that can bind MALTl, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALTl, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALTl, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1 H -indol-2-yl)-2- (trifluoromethyl)-4,7-dihydropyrazolo[1,5- a ]pyrimidin-6-yl)((S)-2-(3- methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I Kur inhibitor

Previously disclosed dihydropyrazolopyrimidines are potent and selective blockers of IKur current. A potential liability with this chemotype is the formation of a reactive metabolite which demonstrated covalent binding to protein in vitro. When substituted at the 2 or 3 position, this template yielded potent IKur inhibitors, with selectivity over hERG which did not form reactive metabolites. Subsequent optimization for potency and PK properties lead to the discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol- 2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S) -2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone (13j), with an acceptable PK profile in preclinical species and potent efficacy in the preclinical rabbit atrial effective refractory period (AERP) model.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.